Visceral fat area and cardiometabolic risk: The Kardiovize study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00075097" target="_blank" >RIV/00159816:_____/21:00075097 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/21:00121420
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S1871403X21000478?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S1871403X21000478?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.orcp.2021.03.005" target="_blank" >10.1016/j.orcp.2021.03.005</a>
Alternative languages
Result language
angličtina
Original language name
Visceral fat area and cardiometabolic risk: The Kardiovize study
Original language description
Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. Methods: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease. Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm(2) (54.8) in men and 89.8 cm(2) (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm(2)(sensitivity = 0.654; specificity = 0.427) and 83 cm(2) (sensitivity = 0.705; specificity = 0.556); Stage 2: 84 cm(2) (sensitivity = 0.673; specificity = 0.551) and 98 cm(2) (sensitivity = 0.702; specificity = 0.628); Stage 3: 90 cm(2) (sensitivity = 0.886; specificity = 0.605) and 109 cm(2) (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm(2)(sensitivity = 0.625; specificity = 0.611) and 81cm(2) (sensitivity = 0.695; specificity = 0.448), respectively. Conclusion: A cut-off value of VFA of 71 cm(2) in men and 83 cm(2) in women exhibited the earliest stage of cardiometabolic risk, and 90 cm(2) in men and 109 cm(2) in women showed the best performance to detect risk. (C) 2021 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Obesity Research & Clinical Practice
ISSN
1871-403X
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
368-374
UT code for WoS article
000675529000010
EID of the result in the Scopus database
—